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INTRODUCTION
Cervical cancer is the second most common cancer
in women and the third leading cause of death in
women worldwide. In 2007, there were approxi-
mately 550,000 new cases and 310,000 deaths per
year. More than 83% of new cases and deaths oc-
cured in developing countries.1,2 In Indonesia, can-
cer is the fifth leading cause of death, and its in-
creasing number associated with a higher female
life expectancy. In Indonesia, cervical cancer is the
most common cancer from based on pathology re-
ports in 2002.3
Abstract
Objectives: To determine the factors that may be used as the prog-
nostic parameter for the therapeutic efficacy of neoadjuvant chemo-
therapy, which can be used to revising the management of early
stage cervical cancer patients with large lesions.
Methods: This was a retrospective cohort study. The study was con-
ducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medi-
cine, University of Indonesia. The subjects were 15 cervical cancer
stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be
treated with neoadjuvant chemotherapy, consisted of cisplatin 50
mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The pa-
tients’ response would be evaluated after completing 3 series of che-
motherapy. Data was retrieved from medical records and cervical bi-
opsy paraffin blocks and examined histopathologically using IHC
staining to see expression of caspase-3 with histoscore assessment
score. Data was analyzed by univariate, bivariate analysis.
Results: Response to PVB neoadjuvant chemotherapy was found in
5 out of 15 patients. None of the clinicopathology variables can be
used to predict response to therapy. Expression of caspase-3 as a
marker of apoptosis, can not predict the response of the therapy be-
fore administrating neoadjuvant chemotherapy either. There is a
significant difference between the levels of caspase-3 in epidermoid
carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI
1.69-21.26).
Conclusion: Clinicopathologic factors and the expression of
caspase-3 before getting chemotherapy neoadjuvant can not predict
the succeed of the therapy.
[Indones J Obstet Gynecol 2013; 1-3: 156-60]
Keywords: caspase -3, clinicopathologic, early-stage cervical cancer
lession in large, neoadjuvant chemotherapy response to therapy
Abstrak
Tujuan: Untuk mengetahui faktor-faktor yang dapat menjadi pa-
rameter prognostik keberhasilan terapi kemoterapi neoajuvan se-
hingga dapat memperbaiki tata laksana penanganan penderita
kanker serviks stadium awal lesi besar.
Metode: Penelitian kohort retrospektif yang dilakukan pada Rumah
Sakit Dr. Cipto Mangunkusomo Fakultas Kedokteran Universitas Indo-
nesia terhadap 15 sampel kanker serviks stadium IB2 dan IIA dengan
lesi > 4 cm yang akan dilakukan pemberian kemoterapi neoajuvan
dengan regimen cisplatin 50 mg/m2, vincristine 2 mg/m2 dan bleo-
mycin 15 mg dan dievaluasi responsnya setelah selesai pemberian
kemoterapi 3 seri. Data diambil dari rekam medis dan blok parafin
biopsi serviks diperiksa histopatologinya dan dilakukan pengecetan
IHK untuk melihat ekspresi kaspase-3 dengan penilaian skor histoskor.
Data dianalisis dengan analisa univariat, bivariat.
Hasil: Respons terhadap kemoterapi neoajuvan PVB ditemukan pada
5 dari 15 subjek. Tidak satupun variabel klinikopatologi yang dapat di
gunakan untuk memprediksi respons terapi. Ekspresi kaspase-3 seba-
gai penanda eksekutor apoptosis sebelum diberikan kemoterapi neo-
ajuvan tidak dapat memprediksi respons terapi. Terdapat perbedaan
bermakna kadar kaspase-3 antara karsinoma epidermoid dengan
adenokarsinoma dengan p 0,02 (RR 6;95% CI 1,69-21,26).
Kesimpulan: Faktor klinikopatologik dan ekspresi kaspase-3 sebelum
mendapatkan kemoterapi neoajuvan tidak dapat memprediksi keber-
hasilan terapi.
[Maj Obstet Ginekol Indones 2013; 1-3: 156-60]
Kata kunci: ekspresi kaspase-3, kanker serviks stadium awal lesi be-
sar, klinikopatologik, neoajuvan kemoterapi, respons terapi
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Patients in the early stages of cervical cancer,
that are stage IB2 and IIA, with the size of the le-
sions > 4 cm, have worse prognosis, and the thera-
peutic modalities of choice still remains controver-
sial. Based on the Figo 2002, there are 3 alternative
of therapeutic modalities, namely primary chemo-
radiation, primary radical hysterectomy and bilat-
eral pelvic lymphadenectomy chemoradiation fol-
lowed by adjuvant chemoradiation, and neoadju-
vant chemotherapy followed by radical hyste-
rectomy and bilateral pelvic lymphadenectomy fol-
lowed by adjuvant radiation or chemoradiation.4
Not all patients give a good response to neoad-
juvant chemotherapy, causing a need of a good pre-
dictor to predict the respond of therapy prior
choosing the primary therapy type.5
Several predicting factors of dynamic cellular ac-
tivity were autophagy, necrosis, mitotic distur-
bance and apoptotic. Some indicators such as Bcl2,
Ki-67, p21, p53, PRB, PCNA (proliferating cell nu-
clear antigen) give varying results. It was stated
that p53, Bcl2, Ki-67 were not good predictor, while
the PRB, PCNA, MDR1, p21 were good predictor.6
The research aims to find out whether clinico-
pathologic factors and examination of the expres-
sion of caspase-3 before administration of neoad-
juvant chemotherapy could be used as a biologic
markers that can predict the response to therapy,
therefore the selection of therapeutic modalities
can be considered in early stage cervical cancer pa-
tients with large lesions.
METHODS
Patients and Methods
A retrospective cohort study conducted at the Dr.
Cipto Mangunkusumo Hospital - Medicine Faculty
University of Indonesia from July 2009 to July 2010
to 15 patients of cervical cancer stage IB2 and IIA
with lesions > 4 cm who would be treated using
neoadjuvant chemotherapy followed by radical
hysterectomy surgery.
Treatment plan: Patients were given neoadjuvant
chemotherapy regiment of PVB (cisplatin, vincristine,
Bleomicyn), with a dose of cisplatin 50 mg/m2 ad-
ministered intravenously, Vincristine 2 mg/m2 ad-
ministered intravenously, and 15 mg Bleomycin ad-
ministered intramuscularly. This regiment were
given for 3 cycles with a 1-week interval.7
Evaluation of treatment response would be per-
formed using RECIST criteria. Complete response
was defined as the the loss of all target lesions,
which was confirmed after > 4 weeks of chemo-
therapy completed. Partial response was a de-
crease of at least 30% of the target lesion, which
refers to the diameter of the initial lesion. Progres-
sive disease was characterized by the increment of
at least 20% from the the diameter of the target
lesion or new lesions encountered. Stable disease
(SD) was defined as the lack of sufficient tumor
shrinkage as to be classified as partial responses.8
Immunohistochemical Assay
Paraffin blocks from the the biopsy was reex-
amined with HE to confirm the diagnosis. Then the
staining of caspase-3 expression by immunohisto-
chemical assay was done. Primary antibodies used
were mouse monoclonal antibody Santa Cruz
Biotechnology, Inc, which was diluted 1,600 times.
The reading of the IHC performed by Immunore-
active score (IRS)/histoscore. Further, data were
analyzed using univariate and bivariate analysis.
Since all the p value was more than 0.025, multi-
variate analysis was not performed.9
RESULTS
Patient Characteristics
Characteristics of 15 patients who received chemo-
therapy are listed in Table 2. Out of 5 subjects, the
mean age, the youngest age and the oldest age
were 45.5 ± 7.50 years, 27 years old 54 years old;
respectively. The highest frequency occurred in the
age group 40-49 years (7/15 or 46.7%) followed
by age group over 50 years (5/15 or 33.3%). Mean
while the mean age of first intercourse was 17.1 ±
2.46 years, and the youngest and the oldest age of
first intercourse were 13 years old and 21 years
old. The highest frequency of marital age was be-
low the age of 20 years (13/15 or 86.7%). The
most common educational level of the subjects was
primary school 6/15 (40%). Most of the subjects
had married once (12), and only 3 subjects have
married at least 2 times. According to the number
of parity, the subject are equally divided into 1-3
parity group (7/15), and 4-6 parity group (7/15).
Distribution normality test of the data of age
groups using Shapiro-Wilk was abnormal with p =
0.08.
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Evaluation of Treatment
Complete response is defined as loss of all tumor
mass. Partial response is defined as 30% or more
reduction in tumor mass, whereas the tumor mass
of less than 30% and progressive is defined as the
onset of new lesions or tumors grow more than
20%. Patients were categorized as respond to ther-
apy in case of complete response and partial re-
sponse, and were considered as unrespond when
there’s are no progressive changes in result. The
success rate of neoadjuvant chemotherapy with
regiment PVB was found in 5 out of 15 subjects.
Clinicopathologic factors showed no significant re-
sults for treatment response, as found in the fol-
lowing Table 1.
Table 1. Response NAC
Therapy Response n(%)
Yes No
Progresive 7 (46.7%)
Stable 3 (20%)
Partial 3 (20%)
Complete 2 (13.3%)
Table 2. Relations between Clinicopathologic Factors and
Response Theraphy
Independent
variable
Response to Theraphy p RR(95%CI)Negative Positive
Age
< 50 years
> 50 years
6 (60%)
4 (40%)
4 (80%)
1 (20%)
1.00 1.33(0.68-2.60)
First sexual intercourse
< 20 years
> 20 years
9 (90%)
1 (10%)
3 (60%)
2 (40%)
0.24 2.25(0.44-11.52)
Education
No education
Elementary
Junior High
Senior High
1 (10%)
4 (40%)
3 (30%)
2 (20%)
1 (20%)
2 (40%)
0 (0%) 
2 (40%)
0.64 —
Married
once
twice
7 (70%)
3 (30%)
5 (100%)
0 (0%)  
1.00 1.71(1.06-2.76)
Parity
1 - 3
> 3
5 (33%)
5 (33%)
2 (13%)
3 (20%)
1.00 0.88(0.43-1.78)
Histopathology assay result
Squamous cell Ca (n=12)
Adenocarcinoma (n=3)
9 (90%)
1 (10%)
3 (60%)
2 (40%)
0.24 0.44(0.09-2.28)
Differentiation
poor (n=4)
intermediate (n=8)
good (n=3)
2 (20%)
7 (70%)
1 (10%)
2 (40%)
1 (20%)
2 (40%)
0.17 —
Lymphovascular stroma invation
positive
negative
2 (20%)
8 (80%)
1 (20%)
4 (80%)
1.00 1.00(0.41-2.45)
Necrosis
positive
negative
5 (50%)
5 (50%)
2 (40%)
3 (60%)
1.00 1.14(0.56-2.33)
Shape
endophitic (n=3)
exophitic (n=12)
2 (20%)
8 (80%)
1 (20%)
4 (80%)
1.00 1.00(0.41-2.45)
Mass
< 4.8 cm
> 4.8 cm
3 (30%)
7 (70%)
2 (40%)
3 (60%)
1.00 1.17(0.51-2.66)
Stage
stage 1 (n=12)
stage 2 (n=3)
8 (80%)
2 (20%)
4 (80%)
1 (20%)
1.00 1.00(0.41-2.45)
Histoscore category
negative (n=10)
positive (n=5)
7 (70%)
3 (30%)
3 (60%)
2 (40%)
1.00 1.17(0.51-2.66)
Table 3 shown that the type of histopathology
provides a significant difference on the expression
of caspase-3 with p 0.02. Other clinicopathologic
factors showed that there was no significant differ-
ence on the expression of caspase-3.
Table 3. Relation between Clinicopathologic and Expres-
sion Caspase-3
Independent
variable
Histoscore/Expressio
n Caspase-3 p RR(95%CI)
Positive Negative
Age
< 50 years
> 50 years
3 (60%)
2 (40%)
7 (70%)
3 (30%)
1.00 1.33(0.31-5.58)
First sexual intercourse
< 20 years
> 20 years
3 (60%)
2 (40%)
9 (90%)
1 (10%)
1.00 1.00(0.17-5.98)
Married
one
twice
4 (80%)
1 (20%)
8 (80%)
2 (20%)
1.00 1.00(0.17-5.98)
Parity
1 - 3
> 3
1 (20%)
4 (80%)
8 (80%)
2 (20%)
0.28 3.5(0.50-24.41)
Histopathology assay result
Squamous cell Ca (n=12)
Adenocarcinoma (n=3)
2 (40%)
3 (60%)
10 (100%)
0 (0%) 
0.24 0.44(0.09-2.28)
Differentiation
poor (n=4)
intermediate (n=8)
good (n=3)
1 (20%)
2 (40%)
2 (40%)
3 (30%)
6 (60%)
1 (10%)
0.61 —
Lymphovascular stroma invation
positive
negative
1 (20%)
4 (80%)
2 (20%)
8 (80%)
1.00 1.00(0.17-5.98)
Necrosis
positive
negative
2 (40%)
3 (60%)
5 (50%)
5 (50%)
1.00 0.76(0.17-3.32)
Shape
endophitic (n=3)
exophitic (n=12)
2 (40%)
3 (60%)
1 (10%)
9 (90%)
0.24 1.00(0.41-2.45)
Mass
< 4.8 cm
> 4.8 cm
1 (20%)
4 (80%)
4 (40%)
6 (60%)
1.00 1.17(0.51-2.66)
Stage
stage 1 (n=12)
stage 2 (n=3)
4 (80%)
1 (20%)
8 (80%)
2 (20%)
1.00 1.00(0.41-2.45)
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DISCUSSION
Primary standard treatment of cervical cancer stage
IB-IIA is surgery, neoadjuvant followed by surgery
or by radiation immediately. Application of two mo-
dalities of treatment will increase morbidity.4
In recent decade, the incidence of cervical cancer
in younger age is increasing (<35 years). Based on
research reports cancer statistics by SEER from the
NCI in 1999-2006, the average age of patients with
cancer was 48 years.10,11 In this research, the mean
age was 45.5 years (SEM [standard error of mean]
1.93) with a span of age was 27-54. The highest
incidence occurred in the age group 40-49 years.
It showed the decline in age of onset of cervical
cancer, possibly due to the implementation of
early detection program that were conducted by
government. Other studies in Indonesia in 2002
showed the highest incidence was in the age group
of 55-64 years.3 In this study 80% of patients had
first sexual intercourse when they were under 20
years. There were no differences in therapeutic re-
sponse in patients with the age group below 50
years than over 50 years, with p = 0.6.
The relationship between clinicopathologic fac-
tors and biological markers have been studied as
a predictor of efficacy in cancer treatment, includ-
ing gynecological.12 Several categories of dynamic
cellular activities that lead to cell death such as
apoptosis, autophagy, necrosis, mitotic destruction
can be used for this purpose. Several indicators of
predictor factors in the administration of chemo-
therapy has been investigated as gene Bcl-2, Ki-67,
p21, p53, PRB, VGEF, MDR1 (Multidrug Resistance),
PCNA (proliferating cell nuclear antigen) with var-
ied results. Bcl-2 and Ki-67 is not a good predictor
with p> 0.05, while the PRB, PCNA, MDR1, and p21
are a good predictor with p <0.05.6,13,14
In this study, clinicopathologic factors of stage,
histological type, differentiation, size of the mass
can not be used as a predictor factor for efficacy of
neoadjuvant chemotherapy treatment, same as the
result that proposed by Panicci, de Jounge et all.8,15-18
In this study, Clinicopathologic factors did not
affect the expression of caspase-3 as an apoptotic
protein that plays a role as an executor of apop-
tosis. All patients who had adenocarcinoma histol-
ogy types showed strong expression of caspase-3
in IHC staining. There were significant differences
compared to other types of squamous cell carci-
noma.
There were five patients with positive appear-
ance of caspase-3, two patients responded to neo-
adjuvant chemotherapy and the three others did
not, and it was not statistically different, with p =
1. Similar to previous studies conducted by de
Jounge and Tsuyoshi19 Ghavami et al found a mu-
tation in the gene caspase-3 thereby making it un-
colored by caspase-3 monoclonal antigen which
were not mutants. Caspase-3 mutations found in
gastric adenocarcinoma, squamous cell carcinoma
and adenocarcinoma of the lung, colon adenocar-
cinoma. The mutation occurs in Exon 6, Exon 5,
Exon 4, is silent and missense mutations.20 Pre-
vious study described that p53 might regulate cell
proliferation and apoptosis induced by chemother-
apy or radiation, but the cancer cells might lose p53
or p53 mutations.
Disruption or mutation in p53 would allow for a
mutation in caspase-3 that play a role as an effector
of apoptosis.17,21-23 Other condition that contrib-
utes to cell death in apoptosis is the variety of sub-
strates to be degraded, so it takes the role of non-
caspase to degrade it. Like Calpain enzymes,
Lysosomes, Protease and the others.22,24 The cell
death that occurs due to chemotherapy is not only
a result of apoptosis pathway, but also result from
other processes such as necrosis, autophagi and
the destruction of mitotic.
Caspase-3, as the effectors of apoptosis, plays an
important role in the process of apoptosis, and
some chemotherapy agents can improve this proc-
ess. In this study, caspase-3 expression does not
affect the effect of neoadjuvant chemotherapy ad-
ministration.
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